Dawa ya kuzuia maambukizi ya Virusi vya UKIMWI yazinduliwa USA

[MELEKAHE]

Mamlaka ya Chakula na Dawa ya Marekani (FDA) imeidhinisha dawa mpya iitwayo Lenacapavir ya kuzuia maambukizi ya Virusi vya UKIMWI, ambayo imeelezwa kupunguza hatari ya maambukizi kwa asilimia 99.9.

Dawa hiyo inayotolewa kwa sindano mara mbili kwa mwaka, itazinduliwa karibuni nchini humo na kusambazwa katika mataifa mengine.

---
Lenacapavir becomes the first and only twice-yearly option for HIV prevention.

The FDA has approved lenacapavir (Yeztugo; Gilead Sciences), a twice-yearly injectable HIV-1 capsid inhibitor, for the prevention of HIV as preexposure prophylaxis (PrEP), according to reports from NBC News, USA Today, and CNBC and a news release from Gilead Sciences.1-4

“This is a historic day in the decades-long fight against HIV. Yeztugo is one of the most important scientific breakthroughs of our time and offers a very real opportunity to help end the HIV epidemic,” Daniel O’Day, chairman and CEO of Gilead Sciences, said in a news release. “This is a medicine that only needs to be given twice a year and has shown remarkable outcomes in clinical studies, which means it could transform HIV prevention."4

Data from pivotal phase 3 trials provided the backing for this approval. In PURPOSE 1 (NCT04994509), lenacapavir was found to be highly effective among trial participants, with 0 HIV infections observed in the lenacapavir group (0/100 person-years; 95% CI, 0.00–0.19) compared with background HIV incidence, which translated to a 100% reduction in HIV infections.5,6

Investigators of PURPOSE 2 (NCT04925752) found that lenacapavir was highly effective at reducing HIV infections among trial enrollees, with 99.9% of participants treated with lenacapavir not acquiring HIV infection in the trial, despite the high reported levels of sexual behavior and sexually transmitted infections observed among trial participants.7,8

In both PURPOSE 1 and 2, patients were highly adherent to lenacapavir injections. At week 26, 91.5% and 91.0% of participants from the respective trials received on-time injections, and at 1 year, these rates were each 92.8%. With lenacapavir only necessitating injections twice-yearly, it now serves as one of the most convenient and effective HIV treatment options available to patients.5,7

Based on these positive trial results, the FDA accepted lenacapavir new drug applications for priority review in early 2025, which followed a breakthrough therapy designation granted by the FDA in October 2024. These processes allowed for lenacapavir to have an expedited review process due to the substantial improvements it could make compared with currently available therapies.9

Lenacapavir was originally developed as a therapy for adults living with HIV who harbored infections resistant or intolerant to available treatments or for whom safety considerations prevented using other PrEP options. In 2022, it received approval from the FDA for patients with HIV-1 infection in heavily treatment-experienced (HTE) adults with multi-drug resistant (MDR) infection.10,11

Source: FDA Approves Twice-Yearly Lenacapavir for HIV Preexposure Prophylaxis

 

[DR SANTOS]

Bei vipi

 

[Carasco Putin]

😃

 

[ndege JOHN]

Ni hapa tu hapa tu

 

[Under-cover]

.

 

[new user2025]

baaaaaaaaas! MMEKWISHAA

 

[Apeche alolo]

Biashara kama kawaida yao si waitoe hio dawa tuu wabuni mwingine. Hio content yao ishaisha muda ni muda wa kuunda mwingine wasitumbue toeni dawa ipo.

 

[buzitata]

View attachment 3375775


Mamlaka ya Chakula na Dawa ya Marekani (FDA) imeidhinisha dawa mpya iitwayo Lenacapavir ya kuzuia maambukizi ya Virusi vya UKIMWI, ambayo imeelezwa kupunguza hatari ya maambukizi kwa asilimia 99.9.

Dawa hiyo inayotolewa kwa sindano mara mbili kwa mwaka, itazinduliwa karibuni nchini humo na kusambazwa katika mataifa mengine.

Ila hawa jamaa wameamua tu kuchezea akili zetu

Ukiona mzungu kaja bongo na anabadilisha sana wanawake usimuige,

Hiyo kinga ipo zaid ya miaka 10 tangu ilipotolewa ila kwakuwa sisi ni kajamba mkundyu wacha tukodoe macho

 

[Detective J]

Biashara kama kawaida yao si waitoe hio dawa tuu wabuni mwingine. Hio content yao ishaisha muda ni muda wa kuunda mwingine wasitumbue toeni dawa ipo.

Kuna ambayo mmeweza kuunda

 

[Aneel munawar]

mzabzab

 

[Tangantika]

Ukimwi sio mwingi kivile, acha kuwaza waza madawa. Madawa nayo huua fiho, msoni nk

Ni hivi pima na mwenzi nenda kafukue vilivyojificha acha uoga wenzio tunazeeeka na ukimwi upo na haujawaji pita tundu lolote na tunendelea na kila kitu cha mtaani. Wengi e waoga kweli na tahadhari nyingi wananasa.
Kuna staff member mchungaji wa mchongo maadili mengi mkewe vijana wanampekea moto kwa ten ya TZ. Sasa uoga wote anaweza letewa ukimwi easily.

 

[Nyarupala]

Wawahishe tu ase😂😂😂

 

[Big Balls]

Nahamia marekani sasa

 

[Cherecheche]

Habari njema hii.

 

[Crazy_Eight]

Jambo jema

 

[VERITE-NUE]

Taasisi ya kudhibiti dawa ya Marekani imeidhinisha dawa mpya ya kuzuia virusi vya Ukimwi.Dawa hiyo inayofanya kazi kwa muda mrefu, Lenacapavir, inahitaji tu kutumika mara moja kila baada ya miezi sita na mwenyekiti wa ugunduzi wake, Daniel O'Day amesema uamuzi wa uongozi wa taasisi ya Chakula na Dawa wa kihistoria katika mapambano dhidi ya VVU.Idhini hiyo inakuja huku utawala wa Rais Trump ukipunguza kufadhili mipango ya afya ya kimataifa ambayo ingesambaza dawa ya Lenacapavir katika nchi zenye kipato cha chini.Lenacapavir, inayouzwa kupitia chapa ya Yeztugo, imeonyesha kupunguza hatari ya maambukizi ya VVU kwa zaidi ya asilimia 99.9 kwa watu wazima na vijana -- hali inayofanya utendaji wake kuwa sawa na chanjo yenye nguvu

 

[Richer]

Shirika la Chakula na Dawa la Marekani (FDA)
limeiidhinisha sindano ya kampuni ya Gilead Sciences-Lenacapavir, kama dawa mpya ya kukinga na kutibu Virusi Vya Ukimwi (VVU) ambayo imechukuliwa kama matumaini makubwa katika mapambano dhidi ya ugonjwa wa UKIMWI duniani.

Dawa hiyo hutolewa kwa sindano moja kila baada ya miezi sita na mara mbili kwa mwaka, jambo litakalopunguza mzigo wa kila siku wa kutumia dawa kama ilivyo kwa kinga nyingi za VVU zinazotumika hivi sasa.

Lenacapavir hufanya kazi kwa kuzuia sehemu ya protini ya virusi inayoitwa capsid, ambayo ni muhimu kwa virusi vya VVU kuweza kuishi na kujiiga ndani ya seli za mwili wa binadamu.

Kwa kulenga capsid, Lenacapavir huzuia hatua mbalimbali za maisha ya virusi ikiwa ni pamoja na kuingia kwenye seli, kuiga muundo mpya, na kutoka nje ya seli ili kuambukiza zingine.

Tafiti zinaonesha kuwa Lenacapavir inaweza pia kutumika kwa ajili ya kuzuia maambukizi ya VVU kwa watu walio katika hatari kubwa, ikiwa kama njia mpya ya PrEP (Pre-Exposure Prophylaxis).

FDA iliidhinisha matumizi ya Lenacapavir mwaka 2022 kwa wagonjwa waliokuwa na chaguzi chache za matibabu. Nchi mbalimbali barani Ulaya na Afrika pia zimeanza mchakato wa kuidhinisha na kuingiza dawa hiyo kwenye mifumo yao ya afya.

Hata hivyo Wizara ya Afya nchini Tanzania bado haijatoa tamko lolote juu ya uwepo wa dawa hizo na uthibitishwaji wake, hivyo wananchi wanapaswa kuendelea kujikinga na maambukizi ya ugonjwa huo.

============
A drug currently used to treat certain HIV infections has also, on Wednesday, received approval from the US Food and Drug Administration to be used to prevent HIV.

Gilead Sciences, maker of the drug, announced that a twice-a-year injection of lenacapavir has been approved in the United States for HIV prevention under the brand name Yeztugo. In clinical trials, the drug was found to dramatically reduce the risk of infection and provide near-total protection against HIV, significantly more than the primary options available for pre-exposure prophylaxis or PrEP.

Therapies called PrEP have been used to prevent HIV infections for years. In the United States, this may involve taking pills, such as a daily medication called Truvada, or getting shots, such as injections every two months of the medication Apretude. But a twice-yearly shot of lenacapavir has now become another option in the prevention toolbox – making it the first and only such shot for HIV prevention.

Source; CNN

 

[Karne]

Zaidi ya 70M/dose ya mwaka mmoja wakati UKIMWI unashika kasi Kusini mwa jangwa la Sahara!

Heri niagize Anaconda ya 2015 halafu niendelee na ndom!

 

[Chivundu]

Walitengeneza "waya" ili kuko control population ya waafrika, wapige hela na badae waje na dawa za kufubaza, badae kuzuia na kutibu kabisa. Kufikia 2030 wataachia dawa na waya utadhibitiwa.

Watakuja na kisa kingine. AIDS is definitely a deal. A well planned scheme. They plan to end AIDS in 2030.

 

[Akhi]

Wazinzi nendeni mkauliwe kidogo kidogo kma ww mwenyewe hujipendi usifikirie atokee mtu wa mbali huko akupende

Never ever forever

UZINZI HAUJAWAHI KUMUACHA MTU SALAMA